Graphic Packaging heads into the back half of 2026 with its first meaningful price recovery in months — yet short sellers are adding positions and the Street remains cautious, setting up a genuine tug-of-war between value hunters and structural skeptics.
The stock jumped 4.8% on Tuesday to close at $11.89, extending a 2% weekly gain and a 9.6% recovery over the past month. That bounce came directly off Q2 earnings results released on August 4. The reaction is notable given how far the stock had fallen — GPK remains well below the $13–14 range it traded in early 2026, and the dividend history in the data shows no payout since mid-2022, removing one traditional support mechanism for packaging names under pressure. The next earnings event isn't until November 3, which means the stock now has three months to trade on fundamentals rather than event catalysts.
Short positioning tells a more complex story than the price action alone suggests. Short interest has edged up to 9.6% of the free float — holding near its highest level of recent months after a sharp drop in mid-June from what appears to have been a temporary spike above 14%. That 9.6% figure represents roughly 28.2 million shares, up about 0.8% over the past month. Borrowing costs are low at 0.44%, down 25% over the past month, which means getting short is cheap and accessible. Availability is ample at 326% — meaning roughly three shares are available to borrow for every one already lent out — well above the 52-week floor of 174%. This is not a squeezed borrow market. The low cost and high availability together suggest the short base is comfortable holding here, with no pressure to cover. Options positioning reinforces the lack of fear on either side: the put/call ratio is running at just 0.07, nearly in line with its 20-day average and near the lower end of its 52-week range of 0.05 to 0.92. There is no options-market panic, but equally no aggressive bullish call-buying.
The Street's message is politely skeptical. Wells Fargo raised its target to $10 on August 5 — today — while maintaining an Underweight rating, the second such target increase in three weeks after lifting it from $8 to $9 on July 15. That pattern tells you the analyst is acknowledging the price recovery, not changing the thesis. JP Morgan initiated coverage at Neutral with an $11.70 target in late June. The mean price target across the Street is $12.24, offering only modest upside from the current $11.89. The bull case rests on tuck-in acquisitions, 5–6% EBITDA growth, and eventual pricing power over commodity inputs. The bear case points to revised EBITDA guidance for Q3 and full-year 2026, persistent weakness in food volumes, oversupply in bleached paperboard, and rising capex — all of which combine to compress free cash flow visibility. Valuation is not stretched: the P/E sits at 10.5, EV/EBITDA at 7.6, and price-to-book below 1. The ORTEX short score is 57.6, modestly above the neutral midpoint and creeping higher over the past two weeks as short interest has gradually rebuilt.
Institutional ownership adds one genuinely interesting data point. BlackRock added over 10 million shares in the quarter ending June 30, lifting its stake to 12.3% of the company — a meaningful accumulation for a passive-leaning manager that typically mirrors index changes. Manning & Napier rebuilt a position of 8.3 million shares in the same period, effectively entering from near-zero. Greenlight Capital, David Einhorn's value-oriented fund, held 9.1 million shares as of March 31. The cluster of value-oriented buyers alongside a persistent short base is the defining tension on this stock.
What to watch between now and November is whether revised EBITDA guidance — the bear case's central concern — stabilises or deteriorates further, and whether the post-earnings bounce at $11.89 holds above the Wells Fargo target that just moved to $10.
See the live data behind this article on ORTEX.
Open GPK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
